Charpentier collects CRISPR/Cas9 tech patents for gene editing in Japan and US

09:36 EDT 22 Jun 2018 | BioPharma-Reporter

ERS Genomics says its patent applications have been approved in the US and Japan, and the pace of license deals has increased to up to four per month.

More From BioPortfolio on "Charpentier collects CRISPR/Cas9 tech patents for gene editing in Japan and US"